Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | GPR35 | Q9HC97 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | TTR | P02766 | 2/20 | 0.40 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.40 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | RARB | P10826 | 1/20 | 0.40 |
| ▸ | COMT | P21964 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10495967 | 0.85 | CYP1A2 (0.70) | CYP1A2GPR35ALDH1A1ERN1TTR | |
| SCHEMBL9781173 | 0.82 | GPR35 (0.45) | CYP1A2GPR35ALDH1A1ERN1CA12 | |
| SCHEMBL30954158 | 0.82 | CYP1A2 (0.56) | CYP1A2GPR35ALDH1A1ERN1TDP1 | |
| SCHEMBL16346720 | 0.80 | ERN1 (0.47) | CYP1A2GPR35ALDH1A1ERN1CA12 | |
| SCHEMBL17378802 | 0.80 | SMN1; SMN2 (0.53) | CYP1A2GPR35ALDH1A1ERN1CA1 | |
| SCHEMBL2925564 | 0.80 | ERN1 (0.59) | CYP1A2GPR35ERN1 | |
| SCHEMBL700219 | 0.79 | CYP1A2 (0.56) | CYP1A2GPR35ALDH1A1CA2TDP1 | |
| SCHEMBL29369262 | 0.79 | CYP1A2 (0.56) | CYP1A2GPR35ALDH1A1CA2TDP1 | |
| SCHEMBL11145998 | 0.78 | CYP1A2 (0.59) | CYP1A2GPR35ALDH1A1TDP1CYP2D6 | |
| SCHEMBL2051718 | 0.78 | CYP1A2 (0.59) | CYP1A2GPR35ALDH1A1TDP1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561563-A2 | TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | Ensem Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-119947718-A | Tricyclic aryl derivatives, and compositions and methods thereof | 昂胜医疗科技公司 | 2025-05-06 | — | — | CN | disclosed |
| WO-2024026129-A2 | TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-7342127-B2 | Substituted anilide ligands for the thyroid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342127-B2 | Substituted anilide ligands for the thyroid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342127-B2 | Substituted anilide ligands for the thyroid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1601641-A4 | SUBSTITUTED ANILIDE LIGANDS FOR THE THYROID RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1601641-A2 | SUBSTITUTED ANILIDE LIGANDS FOR THE THYROID RECEPTOR | Bristol-Myers Squibb Company (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20040180940-A1 | Substituted anilide ligands for the thyroid receptor | KARO BIO AB (SE) | 2004-09-16 | — | — | US | disclosed |
| WO-2004067482-A2 | SUBSTITUTED ANILIDE LIGANDS FOR THE THYROID RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180940-A1 | Substituted anilide ligands for the thyroid receptor | TSHR, TRHR, THRA | CYP1A2 1743/4885GPR35 775/4885ALDH1A1 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.